Zolimomab aritox

Drug Profile

Zolimomab aritox

Alternative Names: Anti-CD5 monoclonal antibody-ricin-chain-A conjugate; Anti-CD5 ricin A chain immunotoxin; CD5 Plus; CD5+; Muromonab; Orthozyme CD5 Plus; Xomazyme CD5 Plus; XZ-CD5

Latest Information Update: 28 Jun 1999

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cancer Research UK
  • Developer Ortho-McNeil; XOMA
  • Class Immunotoxins; Monoclonal antibodies
  • Mechanism of Action CD5 antigen inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Diabetes mellitus; Graft-versus-host disease; Renal transplant rejection; Rheumatoid arthritis

Most Recent Events

  • 28 Jun 1999 Discontinued-II for Rheumatoid arthritis in USA (Unknown route)
  • 18 Aug 1998 No-Development-Reported for Rheumatoid arthritis in USA (Unknown route)
  • 23 Aug 1996 A study in rheumatoid arthritis patients has been added to the side effects and Rheumatic Disease pharmacodynamics and therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top